GENE ONLINE|News &
Opinion
Blog

2022-07-13| Technology

Abbott’s Looks to Treat Depression With Breakthrough Device Status

by Joy Lin
Share To

Abbott has announced that its deep brain stimulation (DBS) system has been granted US FDA Breakthrough Device Designation for treatment-resistant depression (TRD), a form of major depressive disorder. Breakthrough Device status helps speed up the regulatory review process, possibly giving patients earlier access to Abbott’s DBS system. 

“Breakthrough product development always requires bold thinking and collaboration, and Abbott is fully committed to the journey of providing people with new therapeutic options for their treatment-resistant depression,” said Pedro Malha, Vice President of Neuromodulation at Abbott.

Related article: Alleviating Depression and Dementia with Transcorneal Electrical Stimulation

 

A Neurosurgical Solution to Depression

 

Each year, 2.8 million Americans will fail multiple depression treatments and be diagnosed with TRD. The condition is thought to cost the US an estimated $44 billion a year in healthcare, unemployment, and lost productivity. 

DBS is under investigation as a possible treatment for TRD when antidepressants and other device therapies fail. Abbott’s system is designed to be adjusted to the individual’s needs, and involves implanting thin wires called leads into target areas in the brain. The leads are connected to a pulse generator implanted under the skin in the chest, which will produce electrical impulses to modulate abnormal brain activity. 

Abbott’s DBS system has been used in Parkinson’s disease, in which implanted leads regulate abnormal neurons that cause tremor. For TRD, the company has found that implanting electrodes in the part of the brain that regulates mood may reduce disease symptoms. Abbott is now working with the FDA to evaluate the device’s safety and effectiveness for TRD. 

An additional benefit of the system is the ability to be used with Neurosphere Virtual Clinic, a remote platform that allows patients to communicate and receive care from their doctors, all from the comforts of home.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top